期刊文献+

靶向药物和全脑放疗治疗非小细胞肺癌脑转移的研究现状 被引量:7

Research status of targeted drug and whole brain radiotherapy for non-small cell lung cancer with brain metastasis
原文传递
导出
摘要 全脑放疗延长了非小细胞肺癌脑转移患者的生存期,已成为其标准治疗方法.而分子靶向药物的出现是传统意义上的肿瘤治疗观念的一个重大革新,且具有服药方便,起效快,可同时改善颅内及颅外肿瘤病灶,不良反应轻,耐受性好等优点,为非小细胞肺癌脑转移的治疗提供了新的更优治疗方法. Whole brain radiation therapy has become the standard treatment of non-small cell lung cancer (NSCLC) with brain metastasis,because it prolongs the survival times of NSCLC patients with brain metastases.The emergence of molecular targeted drugs is a major innovation in the traditional sense of the cancer treatment.Molecular targeted drugs have many advantages such as convenient dosing,rapid onset,improving the intracranial and extracranial tumor lesions at the same time,mild adverse reactions and good tolerance,which provide a new and better choice for the treatment of NSCLC patients with brain metastases.
出处 《国际肿瘤学杂志》 CAS 2016年第3期216-219,共4页 Journal of International Oncology
关键词 非小细胞肺 肿瘤转移 放射疗法 靶向治疗 Carcinoma,non-small-cell lung Neoplasm metastasis Radiotherapy Targeted therapy
  • 相关文献

参考文献21

  • 1于国华,董丽萍,刘淑真.EGFR基因突变与吉非替尼的疗效和获得性耐药关系的研究概况[J].中华肿瘤防治杂志,2007,14(6):474-476. 被引量:9
  • 2Burel-Vandenbos F, Ambrosetti D, Coutts M, et al. EGFR mutation status in brain metastases of non-small cell lung carcinoma [ J ]. J Neurooncol, 2013, 111 ( 1 ) : 1-10. DOI: 10. 1007/s11060-012- 0990-5.
  • 3Eichler AF, Kahle KT, Wang DL, et al. EGFR mutatiom status and survival after diagnosis of brain metastases in non-small cell lung can- cer[J]. Neuro Oncol, 2010, 12(:11) : 1193-1199. DOI: 10. 1093/ neuonc/noq076.
  • 4Sekine A, Kato T, Hagiwara E, et al. Metastatic brain tumors from non-small cell lung cancer with EGFR mutations: distinguishing in- fluence of exon 19 deletion on radiographic features[ J]. Lung Can- cer, 2012, 77 ( 1 ) : 64-69. DOI: 10. 1016/j. lungcan. 2011. 12. 017.
  • 5Gubens M, Akerley W, Lynch T, et al. A pooled analysis of advanced nonsquamous NSCLC patients with stable treated brain metastases in two phase trials receiving bevacizumab and peme- trexed as second-line therapy, in 14th world conference on lung[ J]. Cancer, 2011, 11 : 3093.
  • 6Park S J, Kim HT, Lee DH, et al. Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation [ J ]. Lung Cancer, 2012, 77(3) : 556-560. DOI: 10. 1016/j. lungcan. 2012.05. 092.
  • 7Heon S, Yeap BY, Lindeman NI, et al. The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small cell lung cancer with EGFR mutations [ J ]. Clin Cancer Res, 2012, 18(16) : 4406-4414. DOI: 10. 1158/1078- 0432. CCR-12-0357.
  • 8Iuehi T, Shingyoji M, Sakalda T, et al. Phase ]I trial of gefitinib alone without radiation therapy for Japanese patients with brain metas- tases from EGFR-mutant lung adenocareinoma [ J ]. Lung Cancer, 2013, 82(2) : 282-287. DOI: 10. lO16/j, lungean. 2013.08. 016.
  • 9Lee HL, Chung TS, Ting LL, et al. EGFR mutations are associated with favorable intraeranial response and progression-free survival following brain irradiation in non-small eell lung cancer patients with brain metastases[J]. Radiat Oneol, 2012, 7: 181. DOI: 10. 1186/ 1748-717X-7-181.
  • 10张洁霞,蔡迪,李时悦,周承志,秦茵茵,欧阳铭.非小细胞肺癌脑转移厄洛替尼和吉非替尼治疗临床比较[J].中华肿瘤防治杂志,2015,22(4):285-288. 被引量:51

二级参考文献69

  • 1张品良,陈黎.易瑞沙治疗晚期非小细胞肺癌53例疗效观察[J].中华肿瘤防治杂志,2006,13(11):851-854. 被引量:8
  • 2王燕,王颖,王彬,王子平,张湘茹,储大同,孙燕.吉非替尼治疗非小细胞肺癌脑转移的初步结果[J].中国肺癌杂志,2006,9(5):447-451. 被引量:33
  • 3张天泽 徐光炜.肿瘤学[M].天津:天津科学技术出版社,1996.1209.
  • 4Kosaka T,Yatabe Y,Endo H,et al.Mutations of the epidermal growth factor receptor gene in lung cancer:biological and clinical implications[J].Cancer Res,2004,64:8919-8923.
  • 5Shigematsu H,Lin L,Takahashi T,et al.Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers[J].JNCI,2005,15:212-217.
  • 6Pao W,Wang T Y,Reily G D,et al.KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib and erlitinib[J].PLOS Medicine,2005,2:57-61.
  • 7Lynch T J.Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non-Small-Cell Lung Cancer to Gefitinib[J].N Engl J Med,2004,350:2129-2139.
  • 8Han S W,Kim T Y,Hwang P G,et al.Preditive and prongostic impact of epidermal growth factor receptor mutation in non-smal cell lung cancer patients treated with gefitinib[J].J Clin Oncol,2005,23:1-9.
  • 9Mitsudomi T,Kosaka T,Endoh H,et al.Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small cell lung cancer[J].J Clin Oncol,2005,11:2513-2520.
  • 10Hoshi S,Yamaguchi T.Recurrence of Non-small-cell lung cancer after successful treatment with Gefitinib-report of three cases[J].Gan ToKagakuRyoho,2004,31(8):1209-1213.

共引文献135

同被引文献48

二级引证文献30

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部